Clinical-stage mRNA medicines company focused on infectious diseases and vaccines.
Symbol: | ARCT |
---|---|
Quote: | 12.81 |
Change: | -0.01 |
Change %: | -0.08% |
High: | 12.87 |
Low: | 12.38 |
Open: | 12.55 |
---|---|
Volume: | 272,394 |
52 Week: | 8.04-45.00 |
P/E Ratio: | -4.27 |
EPS: | -3.00 |
Market Cap: | 347.40 M |
Arcturus Therapeutics Holdings Inc. operates as an advanced-stage clinical biotechnology company specializing in mRNA medicines and vaccines. Founded in 2013 and headquartered in San Diego, California, Arcturus leverages cutting-edge technologies including LUNAR lipid-mediated delivery, STARR mRNA Technology (samRNA), and mRNA drug substance manufacturing.
The company's robust pipeline encompasses RNA therapeutic and vaccine candidates, notably including programs for SARS-CoV-2 (COVID-19) and Influenza. Additionally, Arcturus is advancing treatments for ornithine transcarbamylase (OTC) deficiency, cystic fibrosis, glycogen storage disease type III, and hepatitis B virus through strategic partnerships.
Arcturus' versatile RNA platforms support a range of nucleic acid medicines such as messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. This technological diversity is bolstered by a robust patent portfolio covering its innovations across key global markets including the U.S., Europe, Japan, and China.
Driven by a commitment to scientific excellence and innovation, Arcturus Therapeutics continues to push the boundaries of mRNA-based therapies. By advancing transformative treatments for infectious diseases and genetic disorders, the company aims to improve healthcare outcomes globally and make significant contributions to the field of biotechnology.
Exchange: | NASDAQ |
---|---|
Beta: | 3.414 |
Industry: | Biotechnology |
Sector: | Healthcare |
Employees: | 174 |
IPO Date: | May 22, 2013 |
![]() SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that it will release its financial re... 8 days ago |
![]() The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1. 19 days ago |
![]() Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT ) Q4 2024 Earnings Conference Call March 6, 2025 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations Joe Payne - President and Chief Executive Officer, Director of the Board Andy Sassine - Chief Financial Officer Pad Chivukula - Chief Scientific Officer and Ch... 1 months ago |
![]() Arcturus Therapeutics (ARCT) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.32 per share a year ago. 1 months ago |
![]() SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced its financial results for the fourth ... 1 months ago |